TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note published on Sunday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.54 on Friday. The stock has a 50-day simple moving average of $1.66 and a 200 day simple moving average of $1.80. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP increased its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.